BLS Pharmaceuticals Limited (ASX:BLS)

Australia · Delayed Price · Currency is AUD

1.040

+0.025 (2.46%)

Oct 13, 2026, 4:10 PM AEST

Market Cap	239.52M +198.1%
Revenue (ttm)	73.91M +152.4%
Net Income	15.40M +214.1%
EPS	0.07 +191.3%
Shares Out	230.30M
PE Ratio	15.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	192,313
Open	1.025
Previous Close	1.015
Day's Range	1.015 - 1.050
52-Week Range	0.330 - 1.295
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About BLS Pharmaceuticals

BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol BLS

Full Company Profile

Financial Performance

In fiscal year 2026, BLS Pharmaceuticals's revenue was 73.91 million, an increase of 152.42% compared to the previous year's 29.28 million. Earnings were 15.40 million, an increase of 214.15%.

Financial Statements